Jaishree Bhosle

1.6k total citations
55 papers, 597 citations indexed

About

Jaishree Bhosle is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jaishree Bhosle has authored 55 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Jaishree Bhosle's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (11 papers). Jaishree Bhosle is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Lung Cancer Research Studies (11 papers). Jaishree Bhosle collaborates with scholars based in United Kingdom, United States and Spain. Jaishree Bhosle's co-authors include Mary O’Brien, Sanjay Popat, Anna Minchom, Geoff Hall, Daniel Hochhauser, John A. Hartley, R. Gunapala, M.J. Tilby, Merina Ahmed and Fiona McDonald and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jaishree Bhosle

53 papers receiving 589 citations

Peers

Countries citing papers authored by Jaishree Bhosle

Since Specialization

Citations

This map shows the geographic impact of Jaishree Bhosle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaishree Bhosle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaishree Bhosle more than expected).

Fields of papers citing papers by Jaishree Bhosle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaishree Bhosle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaishree Bhosle. The network helps show where Jaishree Bhosle may publish in the future.

Co-authorship network of co-authors of Jaishree Bhosle

This figure shows the co-authorship network connecting the top 25 collaborators of Jaishree Bhosle. A scholar is included among the top collaborators of Jaishree Bhosle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaishree Bhosle. Jaishree Bhosle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery 2024 ·Lung Cancer ·(unknown), (unknown), Faisal Rehman, (unknown), (unknown), (unknown), (unknown), Nadia Yousaf, (unknown), Carol Tan, Jeremy Smelt, Ian Hunt, Simon Jordan, Sofina Begum, Jaishree Bhosle, Anna Minchom, (unknown), Sanjay Popat, Mary O’Brien, Michael Davidson	0
2	The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment 2022 ·Clinical Oncology ·Xianghua Wu, Rajiv Kumar, (unknown), (unknown), Nicolò Matteo Luca Battisti, Anna Minchom, Jaishree Bhosle, Mary O’Brien	2
3	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond 2021 ·Lung Cancer ·Kroopa Joshi, (unknown), (unknown), (unknown), Nadia Yousaf, Sanjay Popat, Michael Davidson, Jaishree Bhosle, Mary O’Brien, Anna Minchom	5
4	Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications 2021 ·Frontiers in Medicine ·Sumeet Hindocha, (unknown), Merina Ahmed, (unknown), Bhupinder Sharma, Nadia Yousaf, Philip L. Molyneaux, Benjamin Hunter, (unknown), Wanyuan Cui, Michael Davidson, Jaishree Bhosle, Anna Minchom, Imogen Locke, Fiona McDonald, Mary O’Brien, Sanjay Popat, Richard Lee	5
5	180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19 2021 ·Journal of Thoracic Oncology ·Wanyuan Cui, (unknown), (unknown), Jaishree Bhosle, Anna Minchom, Michael Davidson, (unknown), Imogen Locke, Nadia Yousaf, Sanjay Popat, Mary O’Brien	3
6	1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012 2020 ·Annals of Oncology ·Salma K. Jabbour, Byoung Chul Cho, Emilio Bria, Terufumi Kato, Jaishree Bhosle, Justin F. Gainor, Noemı́ Reguart, (unknown), Daniel Morgensztern, Ellen B. Gurary, (unknown), Humberto Lara-Guerra, Martin Reck	4
7	1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond 2020 ·Annals of Oncology ·Kroopa Joshi, (unknown), (unknown), (unknown), Shelize Khakoo, Jaishree Bhosle, Anna Minchom, Mary O’Brien	2
8	Systemic treatment of brain metastases in non-small cell lung cancer 2020 ·European Journal of Cancer ·(unknown), (unknown), Marco Perna, (unknown), (unknown), (unknown), Merina Ahmed, Fiona McDonald, Imogen Locke, Anna Minchom, Jaishree Bhosle, Liam Welsh, Mary O’Brien	75
9	149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction 2018 ·Journal of Thoracic Oncology ·(unknown), Mary O’Brien, Jaishree Bhosle, Nadia Yousaf, Rajiv Kumar, Sanjay Popat, (unknown)	3
10	P3.05-006 Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnea in Lung Cancer and Mesothelioma 2017 ·Journal of Thoracic Oncology ·Anna Minchom, (unknown), Jacqueline Filshie, Jaishree Bhosle, Kofi Nimako, (unknown), R. Gunapala, Sanjay Popat, Mary O’Brien	1
11	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non–Small Cell Lung Cancer: A Single-Center Experience 2017 ·Journal of Thoracic Oncology ·(unknown), (unknown), Mary O’Brien, Jaishree Bhosle, Nicos Fotiadis, Andrew Wotherspoon, Lisa Thompson, Sanjay Popat	21
12	Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit 2017 ·European Journal of Cancer ·Dionysis Papadatos-Pastos, Desam Roda, Maria J. de Miguel, Ann Petruckevitch, (unknown), Marta Capelán, Vasiliki Michalarea, João Paulo da Silveira Nogueira Lima, Nikolaos Diamantis, Jaishree Bhosle, L. Rhoda Molife, Udai Banerji, Johann S. de Bono, Sanjay Popat, Mary O’Brien, Timothy A. Yap	4
13	A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma 2016 ·European Journal of Cancer ·Anna Minchom, (unknown), Jacqueline Filshie, Jaishree Bhosle, Kofi Nimako, (unknown), R. Gunapala, Sanjay Popat, Mary O’Brien	37
14	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice 2015 ·BMC Research Notes ·(unknown), Adam Sharp, (unknown), (unknown), Andrew Wotherspoon, Alexandra Léary, David González de Castro, Jaishree Bhosle, (unknown), (unknown), Sanjay Popat, Timothy A. Yap, Mary O’Brien	5
15	A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients 2015 ·Cancer Chemotherapy and Pharmacology ·Rajiv Kumar, (unknown), Anna Minchom, Adam Sharp, Michael Davidson, R. Gunapala, Timothy A. Yap, Jaishree Bhosle, Sanjay Popat, Mary O’Brien	9
16	Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature 2014 ·Case Reports in Oncology ·Hazel Lote, Jaishree Bhosle, Khin Thway, Kate Newbold, Mary O’Brien	8
17	A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice 2014 ·BMC Cancer ·Mark Linch, Spyridon Gennatas, (unknown), (unknown), R. Gunapala, K. Priest, (unknown), Alison Norton, (unknown), Jaishree Bhosle, Mary O’Brien, Sanjay Popat	26
18	AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines 2014 ·Lung Cancer ·M. Puglisi, P. Thavasu, Andrew N. Stewart, Johann S. de Bono, Mary O’Brien, Sanjay Popat, Jaishree Bhosle, Udai Banerji	21
19	Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression 2013 ·Molecular Cancer Therapeutics ·Jaishree Bhosle, Konstantinos Kiakos, Andrew C.G. Porter, Jenny Wu, Andreas Makris, John A. Hartley, Daniel Hochhauser	9
20	Chemotherapy for advanced non-small cell lung cancer patients with performance status 2 2005 ·Current Opinion in Oncology ·Fiona Blackhall, Jaishree Bhosle, Nicholas Thatcher	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact